Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

EML4‐ALK biology and drug resistance in non‐small cell lung cancer: a new phase of discoveries
Mariam Elshatlawy, Josephina Sampson, K. Clarke, et al.
Molecular Oncology (2023) Vol. 17, Iss. 6, pp. 950-963
Open Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Unveiling the potential effects of resveratrol in lung cancer treatment: Mechanisms and nanoparticle-based drug delivery strategies
Behnam Najafiyan, Zahra Bokaii Hosseini, Samar Esmaelian, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 172, pp. 116207-116207
Open Access | Times Cited: 20
Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions
Hannaneh Parvaresh, Ghazaal Roozitalab, Fatemeh Golandam, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 297-297
Open Access | Times Cited: 15
Novel Amphiphilic PROTAC with Enhanced Pharmacokinetic Properties for ALK Protein Degradation
Shirui Wang, Zhanzhan Feng, Can Qu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 12, pp. 9842-9856
Closed Access | Times Cited: 7
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1539-1549
Closed Access | Times Cited: 7
Emerging regulatory mechanisms and functions of biomolecular condensates: implications for therapeutic targets
Soyoung Jeon, Yong‐Duck Chung, Jae‐Sung Lim, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Non-Classical Pulmonary Exacerbation in Cystic Fibrosis Revealing ALK-Translocated Lung Cancer: A Case Report
Mohamad Hadhud, Johnathan Arnon, Anat Hershko-Moshe, et al.
Respiratory Medicine Case Reports (2025), pp. 102171-102171
Open Access
Stress Response Kinase MK2 Induces Non-canonical Activation of EphA2 in <i>EML4-ALK</i> Lung Cancer Cells
Fang Zhang, Yue Zhou, Naru Hamada, et al.
Biological and Pharmaceutical Bulletin (2025) Vol. 48, Iss. 2, pp. 172-176
Open Access
Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR
Chen Hu, Conghua Lu, Jie Zheng, et al.
Acta Pharmacologica Sinica (2025)
Closed Access
FusOn-pLM: a fusion oncoprotein-specific language model via adjusted rate masking
Sophia Vincoff, Shrey Goel, Kseniia Kholina, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Genomic landscaping of receptor tyrosine kinase ALK with highly frequent rearrangements in cancers
Wei Ye, Wen‐Bin Ou
IUBMB Life (2025) Vol. 77, Iss. 2
Closed Access
Synthesis and Antitumor Activity of 6-(2-Aminobenzo[d]thiazol-5-yl) quinazolin-4(3H)-one Derivatives
Ailing Linghu, L F Tang, Qing Li, et al.
ACS Omega (2025) Vol. 10, Iss. 6, pp. 5686-5698
Open Access
Ensartinib for EML4-ALK-positive lung adenocarcinoma with comorbid mutations in TP53, EGFR, and ERBB2: a case report
Xiaoqing Huang, Lixin Zhou, Jiadong Xia, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Prognostic significance of ALK high expression in SCLC: a 9-year cohort analysis
Jinhe Xu, Wenting Zhang, Feilai Xie, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
An updated patent review of antitumor macrocyclic kinase inhibitors (2019 present)
Xintao He, Lu Chen, Shuangshuang Wu, et al.
Expert Opinion on Therapeutic Patents (2025)
Closed Access
A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance
Xin Li, Zixiong Wang, Chao Chen, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 109015-109015
Open Access | Times Cited: 2
HER3 overexpression: a predictive marker for poor prognosis in advanced ALK-positive non-small cell lung cancer treated with ALK inhibitors
Mee-Jeong Kim, Hyun-min Ju, Ji‐Young Song, et al.
Translational Lung Cancer Research (2024) Vol. 13, Iss. 2, pp. 321-333
Open Access | Times Cited: 2
Long-lasting response to lorlatinib in patients with ALK-driven relapsed or refractory neuroblastoma monitored with circulating tumor DNA analysis
Torben Ek, Raghda R. Ibrahim, Hartmut Vogt, et al.
Cancer Research Communications (2024) Vol. 4, Iss. 9, pp. 2553-2564
Open Access | Times Cited: 2
Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure
Akito Fukuda, Tatsuya Yoshida
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 11, pp. 1157-1167
Closed Access | Times Cited: 5
The rapidly changing field of predictive biomarkers of non-small cell lung cancer
László Tóth, Attila Mokánszki, Gábor Méhes
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 1
Progression patterns, resistant mechanisms and subsequent therapy for ALK-positive NSCLC in the era of second-generation ALK-TKIs
Lige Wu, Zihua Zou, Yan Li, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?
P. Maione, Vincenzo Palma, Giuseppina Pucillo, et al.
Expert Opinion on Therapeutic Targets (2024) Vol. 28, Iss. 8, pp. 659-668
Closed Access | Times Cited: 1
A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review
Zhongzhao Wang, Yang Luo, Heng‐Xin Gong, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib
Jikui Guan, Tzu‐Po Chuang, Anders Vikström, et al.
Frontiers in Oncology (2024) Vol. 13
Open Access
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)
Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Shasha Wang, Xuezhi Hao, Liyuan Dai, et al.
Lung Cancer (2024) Vol. 189, pp. 107503-107503
Closed Access
Page 1 - Next Page

Scroll to top